º£½ÇºÚÁÏ

article

Why We VacciStock-2155992594

DNA vaccine skin patch project awarded funding

Monday, 08 June 2026

An innovation in vaccine delivery that uses a skin patch to administer DNA vaccines has been awarded funding to develop a manufacturing process to enable scale-up of the technology.

Dr James Dixon with colleagues (Dr. Maria Marlow, Dr. David Scurr) in the School of Pharmacy at the º£½ÇºÚÁÏ and project partner Cardiff University have been awarded funding from the second l Platform Funding, UK call.

This project will develop a manufacturing process for a needle-free skin patch that can deliver DNA vaccines and be self-administered without trained healthcare staff. Unlike current vaccines, these patches are stable at room temperature, reducing the need for cold storage and enabling rapid, large-scale distribution.

Using this funding we can now work towards creating a scalable manufacturing process for DNA vaccines using coated microblade patches that can overcome key barriers in vaccine deployment. This technology could transform how vaccines are delivered in the UK and globally, improving access, reducing healthcare burden, and strengthening preparedness for future pandemics.
Dr James Dixon, School of Pharmacy

The team are working with experts in the Faculty of Engineering at the º£½ÇºÚÁÏ (Dr, Geoffery Rivers) to develop and test additive manufacturing processes for the patches that will allow fast and efficient production and ultimately allow the self-delivery of vaccines safely at home.

Dr Dixon explains; “We saw with Covid the need for a vaccine to be developed and deployed very quickly, but there are many barriers to this including the need for cold-storage and delivery of the vaccine with a needle via trained healthcare professionals. Our needle-free patch removes those barriers and we aim to reach a point where we can show that a needle free patch could be developed, manufactured and reach the end used in less than 100 days .”

Dr Dixon is a member of the Nottingham Vaccine Network (NVN) that has 30 º£½ÇºÚÁÏ academics and clinicians developing vaccines across a multitude of human and animal pathogens spanning bacteria, viruses and parasites. The Network’s research spans the entire vaccine production pipeline; from design (including antigen selection by in silico modelling and structural biology), developing novel delivery systems, discovering adjuvants, formulation (with a strong interest in thermostability), through to pre-clinical and clinical testing.

Dr Ruth Griffin from the School of Life Sciences co-founded  the NVN and brokered its membership of the UCL–Oxford Global and Sustainable VaxHubs earlier this year.

I'm thrilled the NVN is already benefiting from this partnership with the world's top players in the vaccine space. Together our Network is driving innovation in vaccines, and we are continuously expanding our network and encouraging new ECRs to join us for opportunities to connect with others and be involved in bid development. By working with other vaccine networks, we share our expertise, models and capabilities and accelerate progress in the development of new and improved vaccines.
Dr Ruth Griffin, School of Life Sciences

Story credits

More information is available from Dr James Dixon on James.Dixon@nottingham.ac.uk 

janeicke
Jane Icke - Media Relations Manager Science
Email: jane.icke@nottingham.ac.uk
Phone: 0115 7486462
Location:

Notes to editors:

About the º£½ÇºÚÁÏ

Ranked 97 in the world and 17th in the UK by the , the º£½ÇºÚÁÏ is a founding member of Russell Group of research-intensive universities. Studying at the º£½ÇºÚÁÏ is a life-changing experience, and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement.

Nottingham was crowned Sports University of the Year by – the third time it has been given the honour since 2018 – and by the .

The university is among the best universities in the UK for the strength of our research, positioned seventh for research power in the UK according to REF 2021. The birthplace of discoveries such as MRI and ibuprofen, our innovations transform lives and tackle global problems such as sustainable food supplies, ending modern slavery, developing greener transport, and reducing reliance on fossil fuels.

The university is a major employer and industry partner - locally and globally - and our graduates are the third most targeted by the UK's top employers, according to The Graduate Market in 2024 report by High Fliers Research. Alongside Nottingham Trent University, we lead the , a pioneering collaboration between the city’s two world-class institutions to improve levels of prosperity, opportunity, sustainability, health and wellbeing for residents in the city and region we are proud to call home.

Media Relations - External Relations

The º£½ÇºÚÁÏ
YANG Fujia Building
Jubilee Campus
Wollaton Road
Nottingham, NG8 1BB

telephone: +44 (0) 115 951 5798
email: pressoffice@nottingham.ac.uk